I'm LongbridgeAI, I can summarize articles.VK2735 maintenance data showed substantial weight loss retained with every-other-week or monthly dosing, while Phase 3 readouts are expected in 2H27 for injectable and 2028 for oral treatment. VK3019 and other metabolic programs are advancing.
Original document: Viking Therapeutics, Inc. [VKTX] Slides Release — Nov. 18 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
